MorphoSys AG (NASDAQ:MOR) will be discussing 3Q20 financial results with the investment community.on 12th November 2020 at 2:00 PM eastern time.
The financial results for the quarter are released after the U.S. market close on Wednesday 11th November 2020
Those interested in listening to the conference call live via the Internet can visit www.morphosys.com
Investors who wish to participate in the conference call may call, +1 877 423 0830 U.S., with passcode : 26740320
Earnings Expectation
MorphoSys AG is reporting third quarter earnings results on Wednesday 11th November 2020, after market close.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 370.45 million ~ $ 382.13 million
Click Here For More Historical Outlooks Of MorphoSys AG
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimers diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases.